Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and …
S Deitelzweig, A Amin, Y Jing… - Journal of medical …, 2012 - Taylor & Francis
Objective: The randomized clinical trials, RE-LY, ROCKET-AF, and ARISTOTLE,
demonstrate that the novel oral anticoagulants (NOACs) are effective options for stroke …
demonstrate that the novel oral anticoagulants (NOACs) are effective options for stroke …
Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and …
S Deitelzweig, A Amin, Y Jing… - Journal of medical …, 2012 - pubmed.ncbi.nlm.nih.gov
Objective The randomized clinical trials, RE-LY, ROCKET-AF, and ARISTOTLE, demonstrate
that the novel oral anticoagulants (NOACs) are effective options for stroke prevention among …
that the novel oral anticoagulants (NOACs) are effective options for stroke prevention among …
Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and …
S Deitelzweig, A Amin, Y Jing… - Journal of Medical …, 2012 - europepmc.org
Objective The randomized clinical trials, RE-LY, ROCKET-AF, and ARISTOTLE, demonstrate
that the novel oral anticoagulants (NOACs) are effective options for stroke prevention among …
that the novel oral anticoagulants (NOACs) are effective options for stroke prevention among …